Which medications in the drug class Antidiabetics, Glucagon-like Peptide-1 Agonists are used in the treatment of Diabetic Nephropathy?

Updated: Oct 09, 2019
  • Author: Vecihi Batuman, MD, FASN; Chief Editor: Romesh Khardori, MD, PhD, FACP  more...
  • Print

Antidiabetics, Glucagon-like Peptide-1 Agonists

These drugs act in the satiety center and reduce appetite, thus helping with weight loss. These drugs promote insulin release, delay glucagon release, and slow gastric emptying and are less likely to cause hypoglycemia.

Exenatide (Bydureon, Byetta)

Exenatide is an incretin mimetic agent that mimics glucose-dependent insulin secretion and several other antihyperglycemic actions of incretins. It improves glycemic control in patients with type 2 DM by enhancing glucose-dependent insulin secretion by pancreatic βcells, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. The drug's 39–amino acid sequence partially overlaps that of the human incretin, GLP-1. It is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes who are taking metformin or a sulfonylurea but have not achieved glycemic control.

Liraglutide (Victoza)

Liraglutide is an incretin mimetic analog of human GLP-1; it acts as a GLP-1 receptor agonist to increase insulin secretion in the presence of elevated blood glucose; it delays gastric emptying to decrease postprandial glucose, and it also decreases glucagon secretion.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!